New Delhi: Mission Madhumeha was launched on 28 October on the occasion of the first National Ayurveda Day. A protocol on ‘Prevention and Control of Diabetes through Ayurveda’ was released for implementing the ‘Mission Madhumeha’. The Madhumeha Assessment Tool (MAT), based on ayurvedic philosophy, has also been developed for self-assessment of the people with regards to possibilities of diabetes.
The Ministry of AYUSH has issued letters to all States, Union Territories, Ayurveda pharmaceutical companies and other stakeholders to celebrate the National Ayurveda Day by organising public talks, seminars, exhibitions etc. on the theme “Ayurveda for prevention and control of Diabetes” as a part of Mission Madhumeha for a complete year.
The anti-diabetic herbal composition for Type II diabetes mellitus (NBRMAP-DB) of trade name BGR34 has been developed by the Council of Scientific & Industrial Research (CSIR) under the category of Ayurvedic Proprietary Medicine as per the Drugs and Cosmetics Act, 1940 (6th Amendment), and has been tested for efficacy and safety in animal models.
The know-how was transferred to AIMIL Pharmaceuticals (India) Ltd, for the manufacture and sale. The licensee has taken forward to hold clinical trials at Agrawal Dharmarth Hospital Society, Shakti Nagar, New Delhi, after due approval from the Ethics Committee of the Hospital on 8 September 2014.
The BGR-34 has shown promising results with respect to glycemic parameters in patients without any adverse reaction. AIMIL launched NBRMAP-DB as BGR-34 in the market on 25 October 2015.
The CSIR has also initiated detailed comprehensive human clinical trial at the Departments of Ayurveda, Institute of Medicines, Banaras Hindu University.
This information was given by Minister of State (Independent Charge) for AYUSH Shripad Yesso Naik in written reply to a question in the Lok Sabha today.